Enanta Pharmaceuticals (NASDAQ: ENTA) insider transactions
In the twelve months to 10 November 2026, executives and directors of Enanta Pharmaceuticals reported 9 open-market sales of 12,883 shares ($183,167) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 8 August 2026 | Rottinghaus Scott T. | Chief Medical Officer | Shares withheld for tax | −1,467 | $13.34 | 23,787 | Form 4 |
| 12 February 2026 | Luly Jay R. | President and CEO | Grant or award | +4,800 | — | 862,826 | Form 4 |
| 12 February 2026 | Luly Jay R. | President and CEO | Grant or award | +15,200 | — | 878,026 | Form 4 |
| 12 February 2026 | Luly Jay R. | President and CEO | Shares withheld for tax | −6,155 | $14.25 | 871,871 | Form 4 |
| 12 February 2026 | Or Yat Sun | Chief Scientific Officer | Grant or award | +1,650 | — | 373,042 | Form 4 |
| 12 February 2026 | Or Yat Sun | Chief Scientific Officer | Grant or award | +5,225 | — | 378,267 | Form 4 |
| 12 February 2026 | Or Yat Sun | Chief Scientific Officer | Shares withheld for tax | −3,413 | $14.25 | 374,854 | Form 4 |
| 12 February 2026 | Rottinghaus Scott T. | Chief Medical Officer | Grant or award | +1,650 | — | 23,442 | Form 4 |
| 12 February 2026 | Rottinghaus Scott T. | Chief Medical Officer | Grant or award | +5,225 | — | 28,667 | Form 4 |
| 12 February 2026 | Rottinghaus Scott T. | Chief Medical Officer | Shares withheld for tax | −3,413 | $14.25 | 25,254 | Form 4 |
| 12 February 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant or award | +1,575 | — | 32,195 | Form 4 |
| 12 February 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | Grant or award | +4,987 | — | 37,182 | Form 4 |
| 12 February 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | Shares withheld for tax | −3,257 | $14.25 | 33,925 | Form 4 |
| 12 February 2026 | Luu Brendan | Chief Business Officer | Grant or award | +1,575 | — | 39,904 | Form 4 |
| 12 February 2026 | Luu Brendan | Chief Business Officer | Grant or award | +4,987 | — | 44,891 | Form 4 |
| 12 February 2026 | Luu Brendan | Chief Business Officer | Shares withheld for tax | −3,257 | $14.25 | 41,634 | Form 4 |
| 12 February 2026 | Kowalsky Matthew Paul | Chief Legal Officer | Grant or award | +1,318 | — | 1,318 | Form 4 |
| 12 February 2026 | Kowalsky Matthew Paul | Chief Legal Officer | Grant or award | +4,175 | — | 5,493 | Form 4 |
| 12 February 2026 | Kowalsky Matthew Paul | Chief Legal Officer | Shares withheld for tax | −1,902 | $14.25 | 3,591 | Form 4 |
| 5 December 2025 | Luly Jay R. | President and CEO | Open-market sale | −4,743 | $14.23 | 858,026 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Enanta Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.